Comparison of MMP-2, MMP-9, COX-2, and PGP Expression in Feline Injection-Site and Feline Noninjection-Site Sarcomas-Pilot Study

Overview

Journal Animals (Basel)

Date 2024 Jul 27

PMID 39061572

Authors

Agata Wojtkowska

Anna Malek

Slawomir Gizinski

Rafal Sapierzynski

Anna Rodo

Justyna Sokolowska

Katarzyna A Zabielska-Koczywas

Anna Wojtalewicz

Magdalena Walewska

Ewa Kautz

Magdalena Ostrzeszewicz

Roman Lechowski

Affiliations

Soon will be listed here.

Abstract

Feline injection-site sarcomas (FISSs) are aggressive neoplasms that have been associated mostly with vaccination. Feline noninjection-site sarcomas (non-FISSs) are less frequently observed in cats and may arise in any anatomic site. This study aimed to determine the differences in the expression of the selected proteins (matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), cyclooxygenase-2 (COX-2), and P-glycoprotein (PGP)) and their correlation with the mitotic count in FISS and non-FISS, in order to characterize their immunohistochemical features. A preliminary study of eleven samples of FISS and eight samples of non-FISS was performed using immunohistochemistry. Among all the tested sarcomas, 80.4% of the tumors were positive for COX-2, 90.2% were positive for MMP-9, and 100% were positive for PGP. The results showed that the expressions of COX-2, MMP-9, and PGP were significantly higher in FISS than in non-FISS (COX-2- ≤ 0.001; MMP-9- ≤ 0.05; and PGP- ≤ 0.05). A Spearman rank correlation analysis showed a moderate negative correlation between the expression of COX-2 and MMP-9 in FISS (r = -0.52). A strong negative correlation between COX-2 and PGP (r = -0.81), a moderate positive correlation between MMP-2 and MMP-9 (r = +0.69), and a moderate negative correlation between MMP-2 and PGP (r = -0.44) were observed in non-FISS. In summary, our study presents the immunohistochemical profile of the proteins involved with inflammation and carcinogenesis in FISS and non-FISS, which can contribute to expanding the knowledge of tumor biology.

References

Gebhard C, Fuchs-Baumgartinger A, Razzazi-Fazeli E, Miller I, Walter I . Distribution and activity levels of matrix metalloproteinase 2 and 9 in canine and feline osteosarcoma. Can J Vet Res. 2016; 80(1):66-73. PMC: 4686036. View

Kass P, Spangler W, Hendrick M, McGill L, Esplin D, Lester S . Multicenter case-control study of risk factors associated with development of vaccine-associated sarcomas in cats. J Am Vet Med Assoc. 2003; 223(9):1283-92. DOI: 10.2460/javma.2003.223.1283. View

Daniele A, Zito A, Giannelli G, Divella R, Asselti M, Mazzocca A . Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res. 2010; 30(9):3521-7. View

Dore M, Lanthier I, Sirois J . Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol. 2003; 40(2):207-12. DOI: 10.1354/vp.40-2-207. View

Hifumi T, Miyoshi N, Kawaguchi H, Nomura K, Yasuda N . Immunohistochemical detection of proteins associated with multidrug resistance to anti-cancer drugs in canine and feline primary pulmonary carcinoma. J Vet Med Sci. 2010; 72(5):665-8. DOI: 10.1292/jvms.09-0519. View

Pang L, Nie M, Corbett L, Knox A . Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. J Immunol. 2003; 170(2):1043-51. DOI: 10.4049/jimmunol.170.2.1043. View

Aresu L, Giantin M, Morello E, Vascellari M, Castagnaro M, Lopparelli R . Matrix metalloproteinases and their inhibitors in canine mammary tumors. BMC Vet Res. 2011; 7:33. PMC: 3141405. DOI: 10.1186/1746-6148-7-33. View

Meuten D, Moore F, George J . Mitotic Count and the Field of View Area: Time to Standardize. Vet Pathol. 2015; 53(1):7-9. DOI: 10.1177/0300985815593349. View

Lukaszewicz-Zajac M, Mroczko B, Szmitkowski M . Gastric cancer - The role of matrix metalloproteinases in tumor progression. Clin Chim Acta. 2011; 412(19-20):1725-30. DOI: 10.1016/j.cca.2011.06.003. View

10.

Jankowski M, Ogilvie G, Lana S, Fettman M, Hansen R, Powers B . Matrix metalloproteinase activity in tumor, stromal tissue, and serum from cats with malignancies. J Vet Intern Med. 2002; 16(1):105-8. DOI: 10.1892/0891-6640(2002)016<0105:mmaits>2.3.co;2. View

11.

Lee J, Tanabe S, Shimohira H, Kobayashi Y, Oomachi T, Azuma S . Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma. Res Vet Sci. 2007; 83(2):210-6. DOI: 10.1016/j.rvsc.2006.12.012. View

12.

Pisamai S, Rungsipipat A, Kunnasut N, Suriyaphol G . Immunohistochemical Expression Profiles of Cell Adhesion Molecules, Matrix Metalloproteinases and their Tissue Inhibitors in Central and Peripheral Neoplastic Foci of Feline Mammary Carcinoma. J Comp Pathol. 2017; 157(2-3):150-162. DOI: 10.1016/j.jcpa.2017.07.004. View

13.

Akoglu H . User's guide to correlation coefficients. Turk J Emerg Med. 2018; 18(3):91-93. PMC: 6107969. DOI: 10.1016/j.tjem.2018.08.001. View

14.

Rizzo M . Cyclooxygenase-2 in oncogenesis. Clin Chim Acta. 2010; 412(9-10):671-87. DOI: 10.1016/j.cca.2010.12.026. View

15.

Niland S, Riscanevo A, Eble J . Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression. Int J Mol Sci. 2022; 23(1). PMC: 8745566. DOI: 10.3390/ijms23010146. View

16.

Chan Y . Biostatistics 104: correlational analysis. Singapore Med J. 2004; 44(12):614-9. View

17.

Larkins T, Nowell M, Singh S, Sanford G . Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer. 2006; 6:181. PMC: 1559713. DOI: 10.1186/1471-2407-6-181. View

18.

Rousset N, Holmes M, Caine A, Dobson J, Herrtage M . Clinical and low-field MRI characteristics of injection site sarcoma in 19 cats. Vet Radiol Ultrasound. 2013; 54(6):623-9. DOI: 10.1111/vru.12067. View

19.

Hartmann K, Day M, Thiry E, Lloret A, Frymus T, Addie D . Feline injection-site sarcoma: ABCD guidelines on prevention and management. J Feline Med Surg. 2015; 17(7):606-13. PMC: 11148925. DOI: 10.1177/1098612X15588451. View

20.

Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J . Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer. 2009; 9:188. PMC: 2706257. DOI: 10.1186/1471-2407-9-188. View